

KIDney Notes

The ASPN Newsletter

FROM THE PRESIDENT



Jodi Smith, MD, MPH, President

ASPN – 2023 Year in Review
Happy New Year to all! It has been a tremendous year for ASPN and I wanted to share some of the highlights from 2023.

ASPN Annual Meeting at PAS– We had a wonderful meeting in Washington DC. Huge thanks to **Kim Reidy** and the entire program committee for all their hard work. It was very

special to be able to celebrate the accomplishments of many of our colleagues.

- ASPN Founders’ Award – **Vicky Norwood (2022) and Blanche Chavers (2023)**
- AAP Henry L. Barnett Awardee - **Tej Matoo**
- ASPN Trainee Research Awards
 - Clinical Science Awardee – **Arthur Lee**
 - Basic Science Awardee – **Michael Michalopoulos**

In addition, we were thrilled to recognize the inaugural winners of our three new awards:

- ASPN Outstanding Service Award - **Sharon Bartosh**
- ASPN Equity, Social Justice and Advocacy Award - **Ray Bignall**
- ASPN Mid Career Award – **Michelle Denburg**

Launch of ASPN’s 4th Strategic Plan - May 2023. It has been exciting to already see the implementation of many of the Strategic Plan initiatives. Here are some highlights:

Contents

- From the President
- From the Editor
- ASPN Leadership
- Corporate Liaison Board
- Committee Updates
 - Advocacy Committee
 - Research Committee
- ASPN Foundation
 - Thank You Donors
- ASPN Call for Awards
- Community Announcements
- ASPN Member of the Month
- ASPN Webinars
- #FOAMed and #SoMe!
- ASPN History Project
- Corporate Liaison Board Corner



Communication/Transparency.

Improving the effectiveness of our communication with all of you has been a major focus of the past year. In February

2023, we launched **KIDney Briefs** - a weekly newsletter serving as a one stop shop for all ASPN announcements as well as kudos to celebrate our colleagues' achievements. The [2022-2023 ASPN Annual Report](#) was added to many of your summer's best beach reading lists! This is the second year of this initiative which communicates all the activities of the 13 ASPN Committees and 10 Interest Groups. As a reminder, the committees and interest groups are open to all Society members at any time of year. Please reach out to info@aspneph.org if you are interested in joining!

On our **ASPEN Tour 2023**, we zoomed in to meet more than 350 of you - pediatric nephrologists, fellows, APPs, nurses, dieticians, and social workers. Thank you for welcoming us! We hope you will have us back for ASPN Tour 2024. ASPN's presence continued to grow on **Social Media** in 2023 thanks to the incredible work of the Communication Committee led by **Sudha Garimella, Sudha Mannemuddhu, and Shweta Shah**. Be on the lookout for the #ASPENFOAM's monthly tweetorials and the Sediment - the official ASPN Podcast. As part of our continued commitment to be an inclusive and transparent organization, we undertook a comprehensive review of the **ASPEN Bylaws** which were last modified in 2018. One important change was that those who serve on the ASPN Nominating Committee will now be elected by ASPN members and serve a set four-year term.



Workforce Summit 2.0. Back in 2019, Pat Brophy convened the first ASPN Workforce Summit where we tackled important issues to help us move forward as a field. Building on the foundation he built, we held the **ASPEN Workforce Summit 2.0** at ASN led by **Danielle Soranno** and the workgroup leaders; **Isa**

Ashoor, Alex Kula, Shina Menon, Michelle Starr, and Darcy Weidemann. There are 5 areas of focus: 1) Defining a clinical FTE, 2) Academic RVUs, 3) Institutional value of nephrology programs, 4) Salary equity for pediatric nephrologists, and 5) Pathway considerations for growth of the pediatric nephrology workforce. One of my most bittersweet memories of 2023 was ASPN's business meeting at ASN where we came together to remember Pat and his dedication to the care of children, his unflagging support of those in our field, and his larger-than-life spirit. Sincere appreciation to **David Hains, Jesse Roach, Joseph Flynn, and Lyndsay Harshman** for sharing their personal memories as we all raised a glass to one of the superheroes of pediatric nephrology.

ASPEN App. Big thanks to the hardworking and dedicated ASPEN App Development and Implementation Taskforce - **Amy Strong, Tamara Hill, Stephanie Nguyen, Brian Stotter, Ryan Town, Arwa Nada, Emily Steinbach, Ari Pollack, Jessica Edmondson** - for their important work on what was identified as one of our highest priority initiatives in the Strategic Plan. The anticipated launch timeframe is late winter. We are sincerely grateful to the **ASPEN Foundation** for generously funding both the Workforce Summit 2.0 and the ASPEN App.

Big Win for ASPEN Advocacy - Prioritizing the Need to Improve Pediatric ESRD Payment. Thanks to ASPEN advocacy, the CMS Calendar Year 2024 ESRD Prospective Payment System and Quality Incentive Program final rule included a **temporary add-on payment for pediatric ESRD services for patients under 18, which would increase reimbursement by 30%**. This is a direct result of ASPN's engagement with the agency providing specific recommendations on how to update the cost reports. This payment will be available for three years while the agency collects data on pediatric care using a revised cost report. More changes to the hospital-based facility cost report are forthcoming. ASPN will be reaching

out to help centers navigate this important change.

Educational Offerings. On behalf of all of ASPN, I want to express my deep gratitude to the organizers of the monthly **ASPN Pathology and Imaging Webinars** - **Robin Kremsdorf, Brian Stotter, Sonal Bhatnagar, Nathan Beins, Abby Basalely, and Diane Liu.** These are terrific learning sessions and I encourage you to zoom in and check them out. The **National Fellows Lectures Series** led by **Arwa Nada, Roshan George, John Mahan, Katherine Twombly, and Darcy Weidemann** was launched in July. Make sure your fellows are not missing out on this! Remember that all of the webinars are archived on the website so you access them any time that works for you. Why watch Netflix when you can learn about Flozins and the Kidney from **Alex Kula**?!? Thank you to **Jason Greenberg and Ken Sutha,** who led ASPN's first **Mini-Mentorship Course** which was filled with 4 sessions of outstanding speakers and stimulating content. Kudos to **Ewa Elenberg** and her team who put together a fabulous program for the **11th Annual ASPN Multidisciplinary Symposium** for almost 100 nephrology nurses, social workers, and dieticians. Looking ahead, we are excited to announce the **Pediatric Critical Care Nephrology Pre-Conference Course at PAS 2024.** Join us in **Toronto on May 3, 2024** for an exciting session with an amazing line-up of speakers and chairs. The first half will cover AKI pathophysiology, fluid balance, utilization of biomarkers, and future therapeutic targets. The second half will focus on pediatric CRRT basics followed by complex case based CRRT management scenarios. Thanks to **Dave Selewski** for leading this effort.

All of these incredible accomplishments were made possible by all of you who generously volunteer your time, expertise, and creativity to help the Society meet the needs of its members and by extension, improve the health of our patients and families living with kidney disease. In particular, I want to recognize and

sincerely thank **Ibrahim Shatat** who is stepping down after more than a decade of expertly running the ASPNeph's Twitter/X account. Ibrahim, words cannot sufficiently express our gratitude for your immense contribution to ASPN!



In closing, the opportunity to work with such dedicated and passionate individuals this past year has been a privilege and I am looking forward to all we will accomplish together in 2024. Please don't hesitate to reach out to me any time at jodi.smith@seattlechildrens.org with any questions or concerns.

Jodi

FROM THE EDITOR

Dear Friends and Colleagues,

With this edition of KIDney Notes, it's humbling to reflect on the year that has passed.

The recent ASPN Town Hall Meeting included updates from the various committees and it's striking to see the hard work and significant impact of each. ASPN is making significant strides in promoting scientific advances and high quality care for our pediatric nephrology patients, but also working to ensure a bright future for our profession

Warmly,

Radha Gajjar

agajjar@childrensnational.org

[@DrRadhaG](#)

Associate Editor

Sudha Mannemuddhu

dr.saisudhamm@gmail.com

[@drM_Sudha](#)

Section Editor

Raja Dandamudi

dandamudi@wustl.edu

[@raja_dandamudi](#)



Follow Us





Jodi Smith, MD, President



Meredith Atkinson, MD, President-Elect



Sandra Amaral, MD, Secretary



Adam Weinstein, MD, Treasurer



Gina-Marie Barletta, MD, Councilor



Annabelle Chua, MD, Councilor



Vikas Dharnidharka, MD, Councilor



Lyndsay Harshman, MD, Councilor



Marva Moxey-Mims, MD, Councilor



Priya Verghese, MD, MPH, Councilor

ASPEN Leadership

OFFICERS

President

Jodi Smith, MD (2023)
Seattle Children's Hospital

Past President

Michael Somers, MD (2023)
Boston Children's Hospital

President Elect

Meredith Atkinson, MD (2023)
Johns Hopkins University School of Medicine

Secretary

Sandra Amaral, MD (2025)
The Children's Hospital of Philadelphia

Treasurer

Adam Weinstein, MD (2024)
Frank H. Netter School of Medicine

COUNCILORS

Gina-Marie Barletta, MD (2024)
University of Arizona

Annabelle Chua, MD (2024)
Duke University Health System

Vikas Dharnidharka, MD (2024)
Washington University School of Medicine

Lyndsay Harshman, MD (2026)
The University of Iowa

Marva Moxey-Mims, MD (2026)
Children's National Hospital

Priya Verghese, MD, MPH (2024)
Northwestern University, Feinberg School of Medicine

Washington Representative

Erika Miller, JD
Cavarocchi Ruscio Dennis Assoc, L.L.C.

NEWSLETTER

Raja Sekhar Dandamudi, MD
Washington University School of Medicine in St. Louis

Radha Gajjar, MD, MSCE
Children's National Hospital

Sai Sudha Mannemuddhu, MD
East Tennessee Children's Hospital

ASPN CORPORATE LIAISON BOARD



ASPN Central Office

Connie Mackay | Executive Director
6728 Old McLean Village Drive | McLean VA | 22101
Phone 703-556-9222 | Fax 703-556-8729
info@aspneph.org | www.aspneph.org

ASPN is managed by Degnon Associates
An accredited professional association management company

COMMITTEE UPDATES

[Click here to learn more about ASPN committees and their membership!](#)

Public Policy Committee

ASPN's 2023 Advocacy Achievements

- Thanks to ASPN's advocacy, CMS proposed and implemented a temporary 30% add-on payment for pediatric dialysis services paid under the End-State Renal Disease Prospective Payment System that will be available from January 1, 2024 through December 31, 2026.
 - ASPN introduced itself to the 118th Congress by sharing information on the organization and our priorities with all 435 members of Congress last February.
 - Working in coalition, ASPN supported the reintroduction of the Living Donor Protection Act and is now advocating to increase the number of co-sponsors.
 - ASPN endorsed the *Living Donor Tax Credit Act*.
 - ASPN President Jodi Smith met with Department of Health and Human Services Secretary Xavier Becerra, Health Resources and Services Administrator Carole Johnson, and Senator Ron Wyden (D-OR) to discuss the impact of the *Securing the U.S Organ Procurement and Transplantation Network Act*, legislation to reform the Organ Procurement and Transplantation Network (OPTN) that ASPN supported.
 - Through engagement with the Food and Drug Administration, ASPN helped address the baby formula and pediatric catheter shortages, providing guidance to members navigating these challenges.
 - ASPN held two Hill days: six members participated in a virtual advocacy day focused on Fiscal Year 2024 appropriations at the end of February and over 20 members came to Washington for our first post-COVID Capitol Hill Day on May 2.
- ASPN President Jodi Smith presented at the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) Kidney Interagency Coordinating Committee (KICC) meeting, highlighting the research gaps in pediatric kidney disease.

2024 Pediatric Centers of Excellence in Nephrology Scientific Symposium

February 9th, 2024 | 12–5pm EST | Virtual

[REGISTER NOW!](#)



Promoting Research in Childhood Kidney Disease

The Pediatric Centers of Excellence in Nephrology invite you to the first Network Scientific Symposium. This meeting will be an opportunity to share research findings from across the NIDDK-funded network and hear from experts and innovators about topics from basic science to clinical research.

Join to network and hear from researchers who have leveraged the PCENs' resources for their research—and learn how you can too!

Keynote talks include:

- **Franz Schaefer MD:** *Filling Evidence Gaps in Pediatric Kidney Disease: Strategies for the Next Decade*
- **Matthias Kretzler MD:** *Targeted Treatments for Glomerular Diseases, from Vision to Reality in 2024*

Follow the **QR Code** or [click here](#) to see our keynote speakers, view the schedule, learn more about the centers, and sign up!



The Pediatric Centers of Excellence in Nephrology are funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)





Thank you to the 2023 donors to the ASPN Foundation!

Carolyn Abitbol
Sabahat Afshan
Sandra Amaral
Isa Ashoor
David Askenazi
Meredith Atkinson
Gina-Marie Barletta
Sharon Bartosh
Frank Boineau
Eileen Brewer
Jennifer Charlton
Olga Charnaya
Blanche Chavers
Robert Chevalier
Annabelle Chua
Donna Claes
Marisa Curiel Garcia
Keefe Davis
Allison Eddy
Bonita Falkner
Joseph Flynn
Ron Frankel
Juan and Ana Gershanik Fund
Roshan George
Larry and Jordan Greenbaum
Coral Hanevold
Erum Hartung
Wendy Hsiao
Abubakr Imam
Julie Ingelfinger
Kathy Jabs
Roberto Jodorkovsky
Frederick Kaskel
Sharon Lagas
Kevin V Lemley
Gary Lerner
Rosalind Lewy
CRD Associates LLC
Megan Lo
Connie Mackay
John Mahan
Mohammad Malekzadeh
Katherine Mayry
Franhe Melean
Joel Melnick
Shina Menon
Erika Miller
Marva Moxey-Mims
Lieuko Nguyen
Victoria Norwood
William Primack
Daniel Ranch
Michelle Rheault
Kelsey Richardson
Jesse Roach
Eloise Salmon
Cheryl and Joshua Samuels
Lauren Schnaper and James Carlton
Kathryn Schubert
Rita Sheth
Douglas Silverstein
Jodi Smith
Irving Smokler
Max Spitzer
Bruder F. Stapleton
Michelle Starr
Caroline Straatmann
Louise Strauss
Agnieszka (Agnes) Swiatecka-Urban
Diane Tenenbaum
Estate Thomas
Priya Verghese
Bradley Warady
Barry Warshaw
Darcy Weidemann
Adam Weinstein
Lynne Weiss
Katherine Westreich
Lynne Yao

ASPN CALL FOR 2024 TRAINEE AWARDS

ASPN/PAS Annual Meeting 2024 Financial Support for Residents and Fellows Trainee Research Awards

Please encourage your pediatric residents and pediatric nephrology fellows to attend our annual meeting.

- Two prestigious trainee research awards will be presented during the **2024 Annual Meeting in Toronto (May 2-6, 2024)**.
- Pediatric residents are eligible for free registration and travel support.
- Pediatric nephrology fellows who are first author on an accepted abstract receive free registration and a stipend.

If you have any questions, contact the ASPN Office by email to info@aspneph.org.

Resident Travel Grant Award

ASPN sponsors **residents and selected other non-fellow trainees** to attend the annual ASPN/PAS meeting.

Stipends to partially support travel (\$400) and complimentary registration are given on a competitive basis. Applicants must be medical students, pediatric residents, chief residents, or med-peds residents currently enrolled in an ACGME-accredited pediatric residency program. Priority is given to those trainees earlier in their education (i.e., PL-1 and PL-2). This grant is restricted to a one-time acceptance. **Applicants must commit to attend the entire meeting if selected.**

The request to be considered must include the following:

- Recommendation by an Active member of the ASPN who agrees to accompany the trainee to the meeting.
- Applicant's curriculum vitae.
- One page statement from the candidate describing his/her interest and possible career plans in pediatric nephrology.

Applications must be submitted by **Wednesday, January 31 2023**.

Complimentary Fellow Registration and Fellow Research Presentation Award

ASPN will cover registration and provide a \$100 honorarium for fellows presently enrolled in ACGME-approved pediatric nephrology training programs who are first author on an accepted abstract.

Questions:

Please contact ASPN's Central Office at info@aspneph.org.

COMMUNITY ANNOUNCEMENTS

PATRICK BROPHY, M.D., MHCDS LECTURESHIP

Letter of Commitment

Dr. Pat Brophy, the Chair of the Department of Pediatrics and Physician-in-Chief at Golisano Children's Hospital (GCH) at URMC from 2018 – 2023, dedicated his career to improving many aspects of health care for children, both from scientific and programmatic perspectives.

In his memory, the Patrick Brophy, M.D., MHCDS Endowed Lectureship will support an annual lecture in the Department of Pediatrics, Advocacy Achievements. The Brophy Lecture will bring local, national, and/or international experts to URMC with the goal of sharing their knowledge to achieve the GCH mission “to help each child reach their full

potential.” Any additional budget not needed for the lectureship may be used to support other academic and programmatic needs in the Department of Pediatrics. Use of the Fund will be at the discretion of the Chair of the Department of Pediatrics.

Gifts to the Endowed Lectureship will be invested alongside the University of Rochester's endowment and will last in perpetuity. While we wait for this endowment to grow over the next several years, we hope to start the Brophy Lecture immediately. Gifts to the Patrick Brophy, M.D., MHCDS Current Use Lectureship will enable us to do just that. Once gifts to the Current Use Lectureship are expended, the Endowed Lectureship will carry on Dr. Brophy's legacy for generations to come.

Please [click here](#) for details on how to support the Patrick Brophy, M.D., MHCDS Lecturship.



[REGISTER NOW!](#)

ASPN MEMBER OF THE MONTH

The Communications Committee is pleased to continue its Member Spotlight series, where we highlight ASPN members and recognize the amazing work that they are doing to support ASPN and the larger nephrology community.

Dr. Loretta Reyes



Dr. Loretta Reyes is an Assistant Professor of Pediatrics at Emory University School of Medicine and Children's Healthcare of Atlanta. She received her medical degree from St. George's University School of Medicine in Grenada, completed pediatric residency

at Driscoll Children's Hospital in Corpus Christi, TX, and pediatric nephrology fellowship at Emory University in Atlanta, GA, where she has remained since completing her nephrology training. Dr. Reyes has a clinical interest in chronic kidney disease and dialysis, but as research-focused faculty, her main career focus is on uremic vasculopathy, including mechanisms underlying endothelial dysfunction and multi-omics and bioinformatics in CKD and vascular disease. Most recently in April of this year, she published her findings on the role of arginine in CKD-associated cardiovascular disease, which can be found in the journal *Nutrients*, entitled "Arginine Dysregulation and Myocardial Dysfunction in a Mouse Model and Children with Chronic Kidney Disease". Her research has been supported by NIDDK T32 and NICHD K12 grants.

Dr. Reyes joined ASPN in 2015 and currently serves as a member of the ASPN Research Committee. She received the ASPN Resident Travel Award in 2011 and the ASPN Fellows Presentation Award in 2018. In the future, she



hopes to take on leadership roles in the Research Committee and is interested in serving on the ASPN PAS Program Committee.

Dr. Reyes grew up on the beautiful twin island Republic of Trinidad and Tobago but currently resides in Atlanta, GA with her husband and two young children. When she is not in the lab, she enjoys hiking, listening to podcasts, experiencing new cultures, and spending time with family and friends.

ASPN WEBINARS



ASPN Webinar

Radiology Webinar

Date: February 5 at 3 PM EST

Subject: 8 month old girl who presents for evaluation of altered mental status

Date: March 4 at 3 PM EST

Subject: AKI after stem cell transplant-TA-TMA

The ASPN webinars are thriving in the zoom meetings with an average of 50+ participants per session and will continue to be offered every first Monday of the month at 3pm ET.

#FOAMed and #SoMe!

What's brewing!!!

Dear PedNeph nephrons,
We are delighted to bring you this new free open-access medical education (#FOAMed) and social media (#SoMe) section. This will include all the related announcements and related projects.

1. ASPN social media (#SoMe) accounts

- ✂ American Society of Pediatric Nephrology (@ASPNeph) / X ([twitter.com](https://twitter.com/ASPNeph))
- 📷 ASPN ([aspneph](https://www.instagram.com/aspneph)) • Instagram photos and videos
- 📘 American Society of Pediatric Nephrology | McLean VA | [Facebook](https://www.facebook.com/ASPNeph)

2. Tweetorials:

📷 [#ASPENFOAM](https://twitter.com/ASPNFOAM) group started in Oct 2020, is a group of 15+ trainees and faculty who put together a monthly tweetorial and infographics.

Latest: [CKD-MBD](#) by [Sasha Pannu](#)
Don't use Twitter? You will find all the mini-reviews in **PDF format**, along with additional FOAMed resources, on the '[#ASPENFOAM group](#)' webpage. If you are interested in joining the group, please get in touch with [Sudha M.](#)

3. Blogposts

The '[LITTLE BEANS](#)' community delivers 'Nephron-size' concepts in pediatric nephrology useful for the wards and the boards.

New posts: [Oral Complications of Chronic Kidney Disease](#) by Patricia Sousa, Shweta S. Shah

Follow [@LittleBeans22](https://twitter.com/LittleBeans22)
If you are interested in writing about interesting or less discussed nephrology topics, join this group amazing group.

- 📌 [KIREports Community](#)
- 📌 [The Renal Fellow Network](#)
- 📌 [The Nephron Power](#)
- 📌 [AJKD Blog](#)
- 📌 [PBfluids.com](#)

4. New Nephrology learning tools



<https://www.visualnephron.com/>

Kidney.wiki

Established in 2021, kidney.wiki is a free, open-access medical education resource for pediatric nephrology intended for use by practitioners and learners at all levels of training. Created by [Ryan Town](#)




5. Journal Clubs

[IPNAJC](#): The official Twitter journal club of the International Pediatric Nephrology Association.
[#IPNAJC](#) Twitter: [@IPNAJC](https://twitter.com/IPNAJC)



Latest JC - October 2023:
Longterm efficacy & safety of Rituximab versus Tacrolimus in children with Steroid dependent nephrotic syndrome. [Summary Infographics](#).


10-Tweet JC: <https://x.com/ipnalc/status/1698380716789370922?s=20>
Previous JC can be located at [IPNAJC](#)
Upcoming JC: in Jan 2024 (Date and Topic TBD)





NephJC is an online medical journal club that utilizes the nephrology (and related specialties) Twitter community to generate discussion and review current literature related to nephrology. **#NephJC** Twitter: [@NephJC](https://twitter.com/NephJC)

6. Nephrology Podcasts:



The Kidney Chronicles by [Emily Zangla](#) is a pediatric nephrology podcast that discusses various PedNeph topics with experts. Latest: Episodes 22-24 on **Leadership from Academia**

to **pharma, Transplant Directorship, & Post Transplant FSGS recurrence** available on [Pod bean](#) and [Spotify](#)! email: doctoremilyz@gmail.com.



The Sediment – the official ASPN Podcast for PAS meeting– Season 3 – from Washington, DC. **#TheSediment #ASPN23** Editor: [Sudha Garimella](#)

5 episodes available on [Podbean](#) &

[Spotify](#)

THE SEDIMENT- season 4 will return in 2024 from Toronto, CA. If you would like to co-host or volunteer, please contact Sudha Garimella at Sudha.Garimella@prismahealth.org.



Channel your enthusiasm

The **Burton Rose book Club** is a podcast that discusses chapters from ‘The Clinical

Physiology of acid-base and electrolyte disorders’. Twitter [@BookBurton](https://twitter.com/BookBurton).

Diuretic draft from 2023 NKF meeting & **Chapter 13** on ‘Meaning and application of urine chemistries’ available on [multiple platforms](#).



Freely filtered is a twice monthly podcast (that is aspirational, not a promise) which discusses recent NephJC journal clubs. They also discuss other significant events in the

world of nephrology. **Latest episodes 61-63** – Bicarb in Transplant, Inaxaplin in APOL 1 kidney disease, & Late breaking and high Impact clinical trial


simultaneous release. Twitter: [@NephJC_Podcast](https://twitter.com/NephJC_Podcast) Available on [multiple platforms](#).

8. [Learn Peritoneal Dialysis](#)

Check out this free interactive training tool aimed at teaching families the basics of peritoneal dialysis, developed by **Drs. Debbie Stein and Kaitlyn Order** from Boston Children’s Hospital.

This is released on OPENPediatrics and includes animated videos and interactive instruction to teach the basics of PD care and is written at a 6th-grade level. It was peer reviewed by a few members of the SCOPE collaborative, and I presented it at their Spring meeting this past May.

This can be accessed at <https://www.openpediatrics.org/learnperitonealdialysis>



See you in next KIDney notes.

S. Sudha Mannemuddhu, MD, FAAP, FASN

[@drM_Sudha](https://twitter.com/drM_Sudha)

dr.saisudham@gmail.com

ASPEN HISTORY PROJECT

Moments in ASPEN History

The first meeting of the ASPEN was held on May 2, 1969, in Atlantic City, New Jersey. The meeting began with a cash bar, followed by dinner and the scientific program, which focused on the role of complement in renal disease, headlined by three renowned speakers. The cost for the speakers was provided by the National Kidney Foundation. Dr. Irwin Lepow and colleagues discovered C1-esterase inhibitor, an enzyme that inhibits the first component of the complement cascade. Besides his research that focused on the immunological mechanisms of renal disease, Dr. Clark West was on the team that performed the first kidney transplant in Ohio, in 1965 and he opened the first dialysis unit for children in Ohio. Dr. Richard Pickering described the role of the complement system in chronic glomerulonephritis.

<u>The Role of Complement in Renal Disease</u>	
Serum Complement: Biochemistry and Immunopathology	Irwin H. Lepow, M.D., Ph.D.
β_1 C Complement: Biochemistry and Behavior in Renal Disease in Children	Clark D. West, M.D.
Complement Profiles in Renal Disease of Children	Richard J. Pickering, M.D.

Corporate Liaison Board Corner

From our CLB Partner:

Now Available:

Data From the Pivotal Clinical Studies PROTECT and DUPLEX

Traverse Therapeutics has presented data demonstrating that sparsentan has the potential to preserve kidney function and significantly delay time to kidney failure compared to an active comparator, suggesting long-term benefits in immunoglobulin A (IgA) nephropathy and focal segmental glomerulosclerosis (FSGS).

Data from the Phase 3 PROTECT and DUPLEX Studies were presented as late-breaking oral presentations at the American Society of Nephrology (ASN) Kidney Week 2023 and simultaneously published in *The Lancet* (PROTECT) and *The New England Journal of Medicine* (DUPLEX).



PROTECT Study

The PROTECT study is a phase 3, global, randomized, multicenter, double-blind, parallel-arm, active-controlled clinical trial evaluating long-term antiproteinuric and nephroprotective efficacy and safety of 400 mg of sparsentan compared to 300 mg of irbesartan in adults with IgA nephropathy.

Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan (SPAR) vs. Irbesartan (IRB) in Patients with Immunoglobulin A Nephropathy (IgAN)

KEY FINDINGS¹

- Sparsentan achieved a significant reduction in proteinuria at 36 weeks (primary endpoint) that was sustained over 110 weeks
- Sparsentan had a clinically meaningful difference in estimated glomerular filtration rate (eGFR) total slope and greater difference in eGFR chronic slope vs irbesartan
- Fewer patients treated with sparsentan progressed to composite kidney failure endpoint compared with patients treated with irbesartan
- Sparsentan was well tolerated and had a safety profile comparable to irbesartan



ClinicalTrials.gov
NCT03762850

Rovin BH et al. *Lancet*. Published online Nov 2, 2023. doi: 10.1016/S0140-6736(23)02302-4



FILSPARI® (sparsentan) is an endothelin and angiotensin II receptor antagonist indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a UPCR ≥ 1.5 g/g. FILSPARI is not approved for treatment of people under the age of 18.

WARNING: HEPATOTOXICITY and EMBRYO-FETAL TOXICITY

Because of the risks of hepatotoxicity and birth defects, FILSPARI is available only through a restricted program called the FILSPARI REMS. Under the FILSPARI REMS, prescribers, patients, and pharmacies must enroll in the program.

See full prescribing information for complete boxed warning.


DUPLEX Study

The DUPLEX study is a global, randomized, multicenter, double-blind, active-controlled, phase 3 trial examining the safety and efficacy of sparsentan as compared to irbesartan in patients aged 8 to 75 years with biopsy-proven FSGS.

Sparsentan (SPAR) vs. Irbesartan (IRB) in Patients with Focal Segmental Glomerulosclerosis (FSGS): Results from the Phase 3 DUPLEX Trial

KEY FINDINGS²

- Largest randomized trial in FSGS reported to date
- Sparsentan achieved a clinically meaningful difference in eGFR chronic slope vs irbesartan; however, the difference was not statistically significant and the primary endpoint was not met
- Sparsentan achieved a clinically meaningful reduction in proteinuria vs irbesartan that was sustained through 108 weeks
- More patients treated with sparsentan reached the FSGS partial remission endpoint (FPRE), defined as urine protein-to-creatinine ratio ≤ 1.5 g/g and $>40\%$ reduction from baseline, after 108 weeks compared with patients treated with irbesartan
- Patients treated with sparsentan achieved complete remission of proteinuria earlier and more frequently compared with patients treated with irbesartan
- Sparsentan was well tolerated and had a safety profile comparable to irbesartan



ClinicalTrials.gov
NCT03493685

Rheault MN et al. *N Engl J Med*. Published online Nov 3, 2023. doi: 10.1056/NEJMoa2308550



Sparsentan is not approved or indicated for treatment of FSGS. The efficacy and safety of sparsentan for FSGS have not been approved by any health authorities.

References:

1. Rovin BH et al. *Lancet*. Published online Nov 2, 2023. doi: 10.1016/S0140-6736(23)02302-4
2. Rheault MN et al. *N Engl J Med*. Published online Nov 3, 2023. doi: 10.1056/NEJMoa2308550

For more information, please contact medinfo@traverse.com.

MA-SP-23-0177 December 2023 ©2023 Traverse Therapeutics, Inc. All rights reserved.



Become a member today



Scan here to view opportunities with IPNA

Why Join IPNA? Membership benefits



Apply & Host IPNA Teaching Course



Membership sign up



2023 – IPNA Application deadlines





IPNA 2025 – Save the Date!



Connect with us!

Follow us on Facebook and Twitter

 IPNA.PedNeph
 @IPNA_PedNeph

Contact us

office@theipna.org

More information

www.theipna.org
www.ipnafoundation.org

